SIMULATIONS PLUS INC

Form 8-K March 07, 2012
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
March 5, 2012
(Date of the earliest event reported)
C'analatiana Diag. La
Simulations Plus, Inc.
(Exact name of registrant as specified in its charter)

California 001-32046 95-4595609

1

(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

42505 10th Street West, Lancaster, California 93534-7059
(Address of principal executive offices) (Zip Code)
661-723-7723
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
C Written communications pursuant to Dule 425 under the Securities Act (17 CED 220 425)
£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£ Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12)
2 Soliciting material pursuant to Rule 142-12 under Exchange Act (17 CFR 240.14a-12)
£ Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))
2 Tre-commencement communications pursuant to Rule 14d-2(0) under Exchange Act (17 CFR 240.14d-2(0))
£ Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
2 110 commencement communications pursuant to Rule 130-4(c) under Exchange Act (17 C1R 240.130-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On March 5, 2012, Simulations Plus, Inc. (the "Company") Board of Directors appointed Mr. John DiBella to the position of Vice President of Marketing and Sales. Mr. DiBella joined the Company's Life Sciences department in 2003 as a Senior Scientist and developed the initial versions of the Company's Dose Disintegration and Dissolution Plus (DDDPlusTM) software for simulating *in vitro* dissolution experiments. Mr. DiBella holds a master's degree in Biomedical Engineering from Case Western Reserve University. He transferred to marketing and sales in 2006. In 2009, he became the Director, Marketing and Sales, achieving consistent sales growth in each quarter since that time.

Item 7.01 Regulation FD Disclosure

On March 6, 2012, the Company issued a press release announcing Mr. John DiBella's appointment. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Exhibits

- (c) Exhibits
- 99.1 Press release issued on March 6, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SIMULATIONS PLUS, INC.

Dated: March 6, 2012 By: /s/ Momoko Beran Momoko Beran Chief Financial Officer

3